The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-22. Anything still debated is marked as such rather than presented as settled.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Linear tetrapeptide | Four residues joined by three peptide bonds |
| Sequence | Ala-Glu-Asp-Gly | Commonly abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free acid form |
| Monoisotopic mass | Approximately 390 Da | Matches values reported from mass spectrometry |
| Net charge near neutral pH | Negative | Contributed by glutamate and aspartate side chains |
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
==== Distribution ==== Enobosarm is a small-molecule and highly lipophilic compound. Compounds of this type are typically able to diffuse freely through biological membranes such as cell membranes and barriers like the blood–brain barrier. This is in fact essential for the action of nuclear receptor ligands like enobosarm since their biological targets (the androgen receptor in this case) are located intracellularly. One in silico study predicted that, on the basis of its overall physicochemical properties (but not considering active transport), enobosarm would be unlikely to cross the blood–brain barrier and hence would be a peripherally selective drug with reduced or no central nervous system effects. However, in a rat tissue distribution study, enobosarm was found to be concentrated in brain tissues to a similar extent as other target tissues like skeletal muscle, bone, prostate, and seminal vesicles. This is consistent with enobosarm producing centrally mediated effects in humans like suppression of LH and FSH secretion. Enobosarm does not bind to sex hormone-binding globulin.
Thorburn Brailsford Robertson (4 March 1884 – 18 January 1930), generally known as Brailsford Robertson, was an Australian academic, physiologist, biochemist, gerontologist, and animal nutritionist. Driven by his view, "Do the best you can with what you have where you are", he was "widely regarded as having possessed a rare capacity both as a teacher and researcher". Robertson's assignment of the rights to his tethelin patent (BR.18, BR.19) to the University of California (UC.6) in September 1917 is universally treated as a landmark precedent event in the subsequent development of what is now known as university technology transfer. His initial research interests were in the physical and biochemical processes underlying nervous activity, cognition, human growth, and senescence. Following the Canadian discovery of insulin, he became deeply involved in both researching the insulin treatment of diabetes mellitus and the Australian production of insulin, which he undertook (in mid-1922) with the direct permission (and precise details of its production) of the Head of the Physiology Department of the University of Toronto, John Macleod, Robertson's former assistant at Toronto, centred on the campus of the University of Adelaide: not only refining and purifying its extraction from bovine pancreases, but also significantly reducing its cost per dose, prior to its full-scale commercial production being transferred to the Commonwealth Serum Laboratories on 1 May 1924.
Another method of possible remediation for CEC is through the use of membrane bioreactors (MBRs) that act through mechanisms of sorption and biodegradation. Membrane bioreactors have shown results on being able to filter out certain solutes and chemicals from wastewater through methods of microfiltration, but due to the extremely small size of CEC, MBRs must rely on other mechanisms in order to ensure the removal of CEC. One mechanism that MBRs use to remove CEC from wastewater is sorption. Sorption of the CEC to sludge deposits in the MBR's system can allow the deposits to sit and be bombarded with water, causing the eventual biodegradation of CEC in the membrane. Sorption of a particular CEC can be even more efficient in the system if the CEC is hydrophobic, causing it to move from the wastewater to the sludge deposits more quickly.
Sources: en.wikipedia.org
As of the Phase Six film Spider-Man: Brand New Day (2026), the "present day" in the MCU is 2028. The following covers and discusses MCU media released by Marvel Studios and the Netflix series by Marvel Television. Loki and What If...? are excluded from the diagram because they occur outside of the main timeline. Werewolf by Night is also excluded, given that the special explicitly does not indicate where it takes place in the MCU. Disney+'s timeline order places the first seasons of Loki and What If...? between Avengers: Endgame and WandaVision, their second seasons after The Marvels, and Werewolf by Night after Thor: Love and Thunder; Werewolf by Night is also placed here in The Marvel Cinematic Universe: An Official Timeline.
17O (n,α) → 14C Some tritium removal facilities make a point of replacing the oxygen of the water with natural oxygen (mostly 16O) to give the added benefit of reducing 14C production. The isotope was first hypothesized and subsequently imaged by Patrick Blackett in Rutherford's lab in 1925: It was a product out of the first man-made transmutation of 14N and 4He2+ conducted by Frederick Soddy and Ernest Rutherford in 1917–1919. Its presence in Earth's atmosphere was later detected in 1929 by Giauque and Johnson in absorption spectra, demonstrating its natural existence.
The Court–Cowan Ministry was the 32nd Ministry of the Government of Western Australia, and was led by Liberal Premier Richard Court and his deputy, the Nationals' Hendy Cowan. It succeeded the Lawrence Ministry on 16 February 1993, following the defeat of the Labor government at the 1993 election ten days earlier. The Ministry was reconstituted on 9 January 1997 following the December 1996 election, due in part to the retirement and resignation of several ministers—Richard Lewis, Kevin Minson, Roger Nicholls and Bob Wiese. The ministry was followed by the Gallop Ministry on 16 February 2001 after the Coalition lost government at the state election held on 16 February.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.
The compound came out of work on epithalamin, a peptide preparation derived from pineal tissue, conducted largely in Russian laboratories. Later studies in other countries examined it mainly in cell cultures and animal models.
The tetrapeptide sequence is a synthetic construct rather than a described circulating peptide. It was derived by analogy to peptide fractions obtained from tissue extracts, not isolated from blood or tissue as such.
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.